<DOC>
	<DOCNO>NCT03060577</DOCNO>
	<brief_summary>ORION-3 Phase II , open-label , non-randomized , active comparator extension trial ass efficacy , safety , tolerability long-term dosing inclisiran evolocumab give subcutaneous injection participant high cardiovascular risk elevate low-density lipoprotein cholesterol ( LDL-C ) .</brief_summary>
	<brief_title>An Extension Trial Inclisiran Compared Evolocumab Participants With Cardiovascular Disease High Cholesterol</brief_title>
	<detailed_description>ORION-3 , extension study MDCO-PCS-15-01 ( ORION-1 ) [ NCT02597127 ] , Phase II , placebo-controlled , double-blind , randomized trial evaluate efficacy , safety , tolerability inclisiran ( ALN-PCSSC ) injection ( ) . All participant complete ORION-1 ( least include Day 210 ) meet study criterion enrol study . ORION-3 long-term extension trial active comparator ( evolocumab ) participant atherosclerotic cardiovascular disease ( ASCVD ) ASCVD-risk equivalent ( diabetes , familial hypercholesterolemia ) elevate LDL-C , despite maximum tolerate dose LDL-C lowering therapy .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>1 . Completion Study MDCOPCS1501 contraindication receive inclisiran evolocumab . 2 . Willing able give write informed consent initiation study related procedure willing comply require study procedure . 3 . Willing selfinject . 1 . Any uncontrolled serious disease , medical surgical condition may either interfere participation clinical study and/or put participant significant risk ( accord investigator 's [ delegate 's ] judgment ) . 2 . An underlie known disease surgical , physical , medical condition , opinion investigator ( delegate ) , might interfere interpretation clinical study result . 3 . Serious comorbid disease life expectancy participant short duration trial ( example , acute systemic infection , cancer , serious illness ) . 4 . Active liver disease define know current infectious , neoplastic , metabolic pathology liver ; unexplained alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) elevation great 2 time upper limit normal ( ULN ) ; total bilirubin elevation great 1.5 time ULN study entry visit . 5 . Females pregnant nursing , childbearing potential unwilling use least two method contraception ( example , oral contraceptive , barrier method , approve contraceptive implant , longterm injectable contraception , intrauterine device ) entire duration study . Exemptions criterion Women &gt; 2 year postmenopausal ( define 1 year longer since last menstrual period ) AND 55 year age Postmenopausal woman ( define ) less 55 year old negative pregnancy test within 24 hour enrollment Women surgically sterilize least 3 month prior enrollment 6 . Males unwilling use acceptable method birth control entire study period ( , condom spermicide ) . 7 . Treatment investigational medicinal product inclisiran device within 30 day five halfË—lives , whichever longer . 8 . Planned use investigational medicinal product inclisiran device course study . 9 . Previous current treatment ( within 90 day study entry ) monoclonal antibody direct towards PCSK9 . 10 . Any condition accord investigator could interfere conduct study , limit : Inappropriate study , include participant unable communicate cooperate investigator . Unable understand protocol requirement , instruction studyrelated restriction , nature , scope , possible consequence study ( include participant whose cooperation doubtful due drug abuse alcohol dependency ) . Unlikely comply protocol requirement , instruction , studyrelated restriction ( example , uncooperative attitude , inability return followup visit , improbability complete study ) . Involved , relative , someone directly involve conduct study . Any known cognitive impairment ( example , Alzheimer 's Disease ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>